File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men

TitleA Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men
Authors
KeywordsAdjuncts
Brachytherapy
Mitomycin C
Steroid
Triamcinolone
Urethral dilatation
Urethral stricture
Urethrotomy
Issue Date2021
Citation
European Urology, 2021, v. 80, n. 4, p. 467-479 How to Cite?
AbstractContext: Urethral stricture disease (USD) is initially managed with minimally invasive techniques such as urethrotomy and urethral dilatation. Minimally invasive techniques are associated with a high recurrence rate, especially in recurrent USD. Adjunctive measures, such as local drug injection, have been used in an attempt to reduce recurrence rates. Objective: To systematically review evidence for the efficacy and safety of adjuncts used alongside minimally invasive treatment of USD. Evidence acquisition: A systematic review of the literature published between 1990 and 2020 was conducted in accordance with the PRISMA checklist. Evidence synthesis: A total of 26 studies were included in the systematic review, from which 13 different adjuncts were identified, including intralesional injection (triamcinolone, n = 135; prednisolone, n = 58; mitomycin C, n = 142; steroid-mitomycin C-hyaluronidase, n = 103, triamcinolone-mitomycin C-N-acetyl cysteine, n = 50; platelet-rich plasma, n = 44), intraluminal instillation (mitomycin C, n = 20; hyaluronic acid and carboxymethylcellulose, n = 70; captopril, n = 37; 192-iridium brachytherapy, n = 10), application via a lubricated catheter (triamcinolone, n = 124), application via a coated balloon (paclitaxel, n = 106), and enteral application (tamoxifen, n = 30; deflazacort, n = 36). Overall, 13 randomised controlled trials were included in the meta-analysis. Use of any adjunct was associated with a lower rate of USD recurrence (odds ratio [OR] 0.37, 95% confidence interval [CI] 0.27–0.50; p < 0.001) compared to no adjunct use. Of all the adjuncts, mitomycin C was associated with the lowest rate of USD recurrence (intralesional injection: OR 0.23, 95% CI 0.11–0.48; p < 0.001; intraluminal injection: OR 0.11, 95% CI 0.02–0.61; p = 0.01). Urinary tract infection (2.9–14%), bleeding (8.8%), and extravasation (5.8%) were associated with steroid injection; pruritis of the urethra (61%) occurred after instillation of captopril; mild gynaecomastia (6.7%) and gastrointestinal side effects (6.7%) were associated with oral tamoxifen. Conclusions: Adjuncts to minimally invasive treatment of USD appear to lower the recurrence rate and are associated with a low adjunct-specific complication rate. However, the studies included were at high risk of bias. Mitomycin C is the adjunct supported by the highest level of evidence. Patient summary: We reviewed studies on additional therapies (called adjuncts) to minimally invasive treatments for narrowing of the urethra in men. Adjuncts such as mitomycin C injection result in a lower recurrence rate compared to no adjunct use. The use of adjuncts appeared to be safe and complications are uncommon; however, the studies were small and of low quality.
Persistent Identifierhttp://hdl.handle.net/10722/328811
ISSN
2023 Impact Factor: 25.3
2023 SCImago Journal Rankings: 6.928
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPang, Karl H.-
dc.contributor.authorChapple, Christopher R.-
dc.contributor.authorChatters, Robin-
dc.contributor.authorDowney, Alison P.-
dc.contributor.authorHarding, Christopher K.-
dc.contributor.authorHind, Daniel-
dc.contributor.authorWatkin, Nick-
dc.contributor.authorOsman, Nadir I.-
dc.date.accessioned2023-07-22T06:24:14Z-
dc.date.available2023-07-22T06:24:14Z-
dc.date.issued2021-
dc.identifier.citationEuropean Urology, 2021, v. 80, n. 4, p. 467-479-
dc.identifier.issn0302-2838-
dc.identifier.urihttp://hdl.handle.net/10722/328811-
dc.description.abstractContext: Urethral stricture disease (USD) is initially managed with minimally invasive techniques such as urethrotomy and urethral dilatation. Minimally invasive techniques are associated with a high recurrence rate, especially in recurrent USD. Adjunctive measures, such as local drug injection, have been used in an attempt to reduce recurrence rates. Objective: To systematically review evidence for the efficacy and safety of adjuncts used alongside minimally invasive treatment of USD. Evidence acquisition: A systematic review of the literature published between 1990 and 2020 was conducted in accordance with the PRISMA checklist. Evidence synthesis: A total of 26 studies were included in the systematic review, from which 13 different adjuncts were identified, including intralesional injection (triamcinolone, n = 135; prednisolone, n = 58; mitomycin C, n = 142; steroid-mitomycin C-hyaluronidase, n = 103, triamcinolone-mitomycin C-N-acetyl cysteine, n = 50; platelet-rich plasma, n = 44), intraluminal instillation (mitomycin C, n = 20; hyaluronic acid and carboxymethylcellulose, n = 70; captopril, n = 37; 192-iridium brachytherapy, n = 10), application via a lubricated catheter (triamcinolone, n = 124), application via a coated balloon (paclitaxel, n = 106), and enteral application (tamoxifen, n = 30; deflazacort, n = 36). Overall, 13 randomised controlled trials were included in the meta-analysis. Use of any adjunct was associated with a lower rate of USD recurrence (odds ratio [OR] 0.37, 95% confidence interval [CI] 0.27–0.50; p < 0.001) compared to no adjunct use. Of all the adjuncts, mitomycin C was associated with the lowest rate of USD recurrence (intralesional injection: OR 0.23, 95% CI 0.11–0.48; p < 0.001; intraluminal injection: OR 0.11, 95% CI 0.02–0.61; p = 0.01). Urinary tract infection (2.9–14%), bleeding (8.8%), and extravasation (5.8%) were associated with steroid injection; pruritis of the urethra (61%) occurred after instillation of captopril; mild gynaecomastia (6.7%) and gastrointestinal side effects (6.7%) were associated with oral tamoxifen. Conclusions: Adjuncts to minimally invasive treatment of USD appear to lower the recurrence rate and are associated with a low adjunct-specific complication rate. However, the studies included were at high risk of bias. Mitomycin C is the adjunct supported by the highest level of evidence. Patient summary: We reviewed studies on additional therapies (called adjuncts) to minimally invasive treatments for narrowing of the urethra in men. Adjuncts such as mitomycin C injection result in a lower recurrence rate compared to no adjunct use. The use of adjuncts appeared to be safe and complications are uncommon; however, the studies were small and of low quality.-
dc.languageeng-
dc.relation.ispartofEuropean Urology-
dc.subjectAdjuncts-
dc.subjectBrachytherapy-
dc.subjectMitomycin C-
dc.subjectSteroid-
dc.subjectTriamcinolone-
dc.subjectUrethral dilatation-
dc.subjectUrethral stricture-
dc.subjectUrethrotomy-
dc.titleA Systematic Review and Meta-analysis of Adjuncts to Minimally Invasive Treatment of Urethral Stricture in Men-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.eururo.2021.06.022-
dc.identifier.pmid34275660-
dc.identifier.scopuseid_2-s2.0-85110498046-
dc.identifier.volume80-
dc.identifier.issue4-
dc.identifier.spage467-
dc.identifier.epage479-
dc.identifier.eissn1873-7560-
dc.identifier.isiWOS:000696981000017-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats